The 2023 Chinese Medical Association Annual Conference on Organ Transplantation (CSOT) concluded successfully

The "2023 Chinese Medical Association Organ Transplantation Annual Conference" sponsored by the Chinese Medical Association and the Organ Transplantation Branch of the Chinese Medical Association and hosted by the First Affiliated Hospital of Xi'an Jiaotong University opened grandly on the morning of September 25, 2023 in Xi'an, the ancient capital of thirteen dynasties and the starting point of the Silk Road. Nearly 2,000 experts and medical workers from domestic and foreign fields related to organ transplantation gathered at the shore of Bashui for the grand event.

Relevant colleagues from the Medical Department and Marketing Department of AlloDx attended this meeting and showcased the company's latest products and technologies in the field of organ transplantation diagnosis, especially the latest clinical application data of the Ankang non-invasive test (AlloK seq®), attracting a large number of experts, scholars and industry insiders to come and communicate.

During the meeting, academic reports by multiple experts demonstrated the clinical application data of AlloK seq®, which resonated with the audience.

my country's organ transplantation field has achieved today's achievements and demonstrated extraordinary influence in the world. It relies on the hard work of transplantation experts and their continuous climb to the peak of transplantation medicine. In the future, AlloDx looks forward to sincere cooperation and common development with more colleagues to provide more and better products and services in the field of transplantation medicine.

About AlloDx
AlloDx (AlloDx) was established in 2018. It focuses on the research and development of new generation molecular diagnostic technology and clinical transformation in the field of organ transplantation. It is a national high-tech enterprise and a science and technology small and medium-sized enterprise of the Ministry of Science and Technology. It has won honors such as Shanghai's 2021 Science and Technology Small and Medium Enterprises Innovation Fund Support. Up to now, it has 15 core invention patents, 23 software copyrights, published 18 ddcfDNA-related articles, including 14 SCI articles, and 6 collaborative research results were invited to give oral reports (Oral) at the International Annual Conference on Transplantation. At present, more than 7,000 ddcfDNA samples have been tested, making it the largest “China Organ Transplantation ddcfDNA Gene Database”.